Since MIT’s pioneering work on 40 Hz stimulation (the GENUS approach — Gamma ENtrainment Using Sensory stimulation), the idea of inducing gamma oscillations through light and sound has drawn major interest in neurodegeneration research.
The rationale
In mouse models of Alzheimer’s disease, exposure to light flickering at 40 Hz, then to 40 Hz pulsed sound, was associated with reduced amyloid load and an increased microglial response in some brain regions. The hypothesis: restoring deficient gamma oscillations might support clearance of pathological aggregates.
Moving to humans
Early-phase clinical trials (safety, feasibility) show that 40 Hz audiovisual stimulation is well tolerated. Some report encouraging signals on functional connectivity, sleep or slowed atrophy, but results on cognition remain preliminary and inconsistent across cohorts.
Methodological caution
- Preclinical effects do not transfer automatically to humans
- Heterogeneous protocols (exposure duration, modality, disease stage)
- Need for large randomised phase III trials
Key message
40 Hz stimulation is a serious, active therapeutic avenue, but it is not a validated treatment for Alzheimer’s disease. This rigorous clinical research must be distinguished from consumer « 40 Hz sounds » sold as memory boosters, which rest on no equivalent evidence of efficacy.
Sources & references
Iaccarino H.F. et al., "Gamma frequency entrainment attenuates amyloid load and modifies microglia", Nature, 2016.
Martorell A.J. et al., "Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology", Cell, 2019.
Chan D. et al., 40 Hz clinical trials, 2022–2024.
This article is for informational purposes only and does not replace professional medical advice.